首页> 美国卫生研究院文献>MedChemComm >Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties
【2h】

Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties

机译:含氮芥子气和2-氨基苯甲酰胺部分的DNA / HDAC双靶向抑制剂的合理设计和表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Histone deacetylases (HDACs) play a key role not only in gene expression but also in DNA repair. Herein, we report the rational design and characterization of a compound named chlordinaline containing nitrogen mustard and 2-aminobenzamide moieties as a DNA/HDAC dual-targeting inhibitor. Chlordinaline exhibited moderate total HDAC inhibitory activity. The HDAC isoform selectivity assay indicated that chlordinaline mostly inhibits HDAC3. Chlordinaline exhibited both DNA and HDAC inhibitory activities and showed potent antiproliferative activity against all the six test cancer cell lines with IC50 values of as low as 3.1–14.2 μM, which is significantly more potent than reference drugs chlorambucil and tacedinaline. Chlordinaline could induce the apoptosis and G2/M phase cell cycle arrest of A375 cancer cells. This study demonstrates that combining nitrogen mustard and 2-aminobenzamide moieties into one molecule is an effective method to obtain DNA/HDAC dual-targeting inhibitors as potent antitumor agents. Chlordinaline as the first example of such DNA/HDAC dual-targeting inhibitors could be a promising candidate for cancer therapy and could also be a lead compound for further optimization.
机译:组蛋白脱乙酰基酶(HDAC)不仅在基因表达中而且在DNA修复中都起着关键作用。在本文中,我们报告了一种合理的设计和特征,该化合物名为chlordinaline,其中含有氮芥子气和2-氨基苯甲酰胺部分作为DNA / HDAC双靶抑制剂。氯地那林显示出中等的总HDAC抑制活性。 HDAC同工型选择性测定表明,氯地那林主要抑制HDAC3。盐酸氯地那林同时具有DNA和HDAC抑制活性,并且对所有六种测试癌细胞系均显示出强效的抗增殖活性,IC50值低至3.1–14.2μM,远比参考药物苯丁酸氮芥和他克西那林有效。氯地那林可诱导A375癌细胞凋亡和G2 / M期细胞周期阻滞。这项研究表明,将氮芥子气和2-氨基苯甲酰胺部分结合到一个分子中是一种有效的方法来获得作为有效抗肿瘤剂的DNA / HDAC双靶向抑制剂。氯地那林作为此类DNA / HDAC双靶向抑制剂的第一个实例可能是癌症治疗的有希望的候选者,也可能是进一步优化的先导化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号